CME Group Stock Topped The Consensus In Q1, Is It A Buy?

+26.54%
Upside
192
Market
243
Trefis
CME: CME Group logo
CME
CME Group

CME Group’s stock (NYSE: CME) has lost 1% YTD, while the S&P500 is down 12% over the same period. Further, at its current price of $226 per share, it is trading 7% below its fair value of $243 – Trefis’ estimate for CME Group’s valuationThe exchange posted better than expected earnings in the recently released first-quarter results, with net revenues increasing by 7% y-o-y to $1.35 billion. This could be attributed to slight growth in clearing and transaction fees. Total average daily volume (ADV) was 25.9 million contracts in Q1 – up 19% y-o-y, primarily driven by higher equity indexes and interest rate contracts. However, the average rate per contract (RPC) witnessed a marginal decrease. Overall, the adjusted net income increased 22% y-o-y to $702 million. It was partly because of revenue growth and partly due to a drop in total expenses as a % of revenue from 42% to 36%.

The company’s net revenues decreased 4% y-o-y to $4.7 billion in 2021. The drop was due to a decrease in clearing & transaction fees, and lower other revenues, partially offset by a 6% rise in the market data & information services category. While the ADV improved 3% y-o-y in the year, it was more than offset by a 5% drop in the RPC. That said, the adjusted net income still improved 24% y-o-y to $2.6 billion. It was due to a slight decrease in the total expenses as a % of revenues, coupled with higher investment income and higher equity in net earnings of unconsolidated subsidiaries.

The securities market has seen a significant spike in trading volumes since the first quarter of 2020. However, we expect the trading volumes to normalize over the subsequent quarters, with a recovery in the economy. That said, the non-trading revenues are likely to drive growth for the company. Overall, CME Group revenues are expected to touch $5.1 billion in FY2022. Additionally, CME’s adjusted net income is likely to grow 10% y-o-y to $2.9 billion in the year. This coupled with an annual EPS of $8.05 and a P/E multiple of just above 30x will lead to the valuation of $243.

Relevant Articles
  1. CME Group Stock To Miss The Earnings Consensus In Q4?
  2. Is CME Group Stock Fairly Priced?
  3. Earnings Beat In The Cards For The CME Group Stock In Q3?
  4. What’s Next For CME Group Stock After Its 5.5% Rise In A Week?
  5. CME Group Stock Is Trading 13% Below Its Fair Value
  6. What To Expect From CME Group Stock In Q2?

Here you’ll find our previous coverage of CME Group stock, where you can track our view over time.

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Apr 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 CME Return -5% -1% 96%
 S&P 500 Return -8% -12% 87%
 Trefis Multi-Strategy Portfolio -7% -14% 236%

[1] Month-to-date and year-to-date as of 4/29/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates